Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS‐CoV‐2 and a Multitude of Pathological Viruses In Vitro
Palayakotai Raghavan
Abstract
Increasing outbreaks of new pathogenic viruses have promoted the exploration of novel alternatives to time‐consuming vaccines. Thus, it is necessary to develop a universal approach to halt the spread of new and unknown viruses as they are discovered. One such promising approach is to target lipid membranes, which are common to all viruses and bacteria. The ongoing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has reaffirmed the importance of interactions between the virus envelope and the host cell plasma membrane as a critical mechanism of infection. Metadichol®, a nanolipid emulsion of long‐chain alcohols, has been demonstrated as a strong candidate that inhibits the proliferation of SARS‐CoV‐2. Naturally derived substances, such as long‐chain saturated lipid alcohols, reduce viral infectivity, including that of coronaviruses (such as SARS‐CoV‐2) by modifying their lipid‐dependent attachment mechanism to human host cells. The receptor ACE2 mediates the entry of SARS‐CoV‐2 into the host cells, whereas the serine protease TMPRSS2 primes the viral S protein. In this study, Metadichol® was found to be 270 times more potent an inhibitor of TMPRSS2 (EC 50 = 96 ng/mL) than camostat mesylate (EC 50 = 26000 ng/mL). Additionally, it inhibits ACE with an EC 50 of 71 ng/mL, but it is a very weak inhibitor of ACE2 at an EC 50 of 31 μ g/mL. Furthermore, the live viral assay performed in Caco‐2 cells revealed that Metadichol® inhibits SARS‐CoV‐2 replication at an EC 90 of 0.16 μ g/mL. Moreover, Metadichol® had an EC 90 of 0.00037 μ M, making it 2081 and 3371 times more potent than remdesivir (EC 50 = 0.77 μ M) and chloroquine (EC 50 = 1.14 μ M), respectively.